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Abstract
Background: Targeting tumor vasculature is a strategy with great promise in the treatment of many cancers.
However, anti-angiogenic reagents that target VEGF/VEGFR2 signaling have met with variable results clinically.
Among the possible reasons for this may be heterogeneous expression of the target protein.
Methods: Double immunofluorescent staining was performed on formalin-fixed paraffin embedded sections of
treated and control SW480 (colorectal) and WM239 (melanoma) xenografts, and tissue microarrays of human
colorectal carcinoma and melanoma. Xenografts were developed using RAG1
-/- mice by injection with WM239 or
SW480 cells and mice were treated with 20 mg/kg/day of cyclophosphamide in their drinking water for up to 18
days. Treated and control tissues were characterized by double immunofluorescence using the mural cell marker
a-SMA and CD31, while the ratio of desmin/CD31 was also determined by western blot. Hypoxia in treated and
control tissues were quantified using both western blotting for HIF-1a and immunohistochemistry of CA-IX.
Results: VEGFR2 is heterogeneously expressed in tumor vasculature in both malignant melanoma and colorectal
carcinoma. We observed a significant decrease in microvascular density (MVD) in response to low dose
metronomic cyclophosphamide chemotherapy in both malignant melanoma (with higher proportion VEGFR2
positive blood vessels; 93%) and colorectal carcinoma (with lower proportion VEGFR2 positive blood vessels; 60%)
xenografts. This reduction in MVD occurred in the absence of a significant anti-tumor effect. We also observed less
hypoxia in treated melanoma xenografts, despite successful anti-angiogenic blockade, but no change in hypoxia of
colorectal xenografts, suggesting that decreases in tumor hypoxia reflect a complex relationship with vascular
density. Based on a-SMA staining and the ratio of desmin to CD31 expression as markers of tumor blood vessel
functionality, we found evidence for increased stabilization of colorectal microvessels, but no such change in
melanoma vessels.
Conclusions: Overall, our study suggests that while heterogeneous expression of VEGFR2 is a feature of human
tumors, it may not affect response to low dose metronomic cyclophosphamide treatment and possibly other anti-
angiogenic approaches. It remains to be seen whether this heterogeneity is partly responsible for the variable
clinical success seen to date with targeted anti-VEGFR2 therapy.
Background
Solid tumors rely on a robust vascular supply for growth
and spread to distant sites, thus blocking tumor growth
by disrupting angiogenesis is a rational anti-cancer
strategy and several targeted therapies are currently
approved or are in clinical trial [1]. Conventional
cytotoxic chemotherapy is administered at maximum
tolerated doses (MTD) every 2-3 weeks, but when the
same agents are administered on a low does metro-
nomic (LDM) schedule (i.e. more frequently and at 10
fold or lower concentration), an anti-angiogenic effect
occurs [2]. For example, vinblastine at ultra low doses
(≤ 1 pmol/L) inhibits endothelial cell proliferation,
migration and metalloproteinase secretion in vitro and
in vivo. Paclitaxel, cyclophosphamide, and docetaxel
exhibit similar effects on endothelial cells when given as
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sphamide has been shown to exert its effect through the
induction of thrombospondin-1 (TSP-1), which presum-
ably exerts its anti-angiogenic effects via binding to the
receptor CD36 on the surface of endothelial cells [5].
TSP-1 can also bind and sequester VEGF, effectively
inhibiting its pro-angiogenic effects [6]. VEGF activation
of VEGFR2 (KDR; flk-1) is considered to be the major
signal transduction event leading to both physiological
and pathological angiogenesis [7].
Tumor blood vessels are structurally and functionally
abnormal, resulting in relatively inefficient tissue perfu-
sion despite high vascular density [8,9]. Administration
of anti-angiogenic drugs should induce a reduction in
tumor vessel density, due to destruction of unstable ves-
sels and/or prevention of new sprouting. Anti-angio-
genic agents may also generate a normalization window,
where the tumor vasculature reverts to a more regular
and organized state characterized by increased tumor
oxygenation, improved drug penetration, and decreased
interstitial fluid pressure[10-13]. While LDM cyclopho-
sphamide did not induce significant blood vessel nor-
malization in the RIP1-Tag2 pancreatic insulinoma
model [14], it is not known whether vessels recruited to
xenografted human cancer will be normalized by this
therapeutic approach.
Previous work in our laboratory reported heteroge-
neous vascular expression of the Tie2/TEK receptor tyr-
osine kinase in some xenografted tumors, which were
refractive to Tie2 inhibition[15]. Since variation in other
receptor molecules could impact the effectiveness of
anti-angiogenic agents, here we evaluate patterns of
VEGFR2 expression by tumor vasculature, and explore
the therapeutic impact of heterogeneous VEGFR2
expression during response to low dose metronomic
cyclophosphamide using colorectal cancer and malig-
nant melanoma tumors.
Methods
Cell Lines
Human malignant melanoma (WM239) and colorectal
carcinoma (SW480) cell lines were obtained from the
American Type Culture Collection (Manassas, VA,
USA). Cells were cultured in DMEM (Sigma-Aldrich,
Oakville, ON, Canada) containing 10% fetal bovine
serum (FBS) (Invitrogen, Burlington, ON, Canada), 1%
sodium pyruvate (Sigma-Aldrich), and 0.5% gentamicin
(Invitrogen) and maintained in a humidified atmosphere
at 37°C and 5% CO2.
Xenografts
All animal studies were performed according to regula-
tions of the Canadian Council on Animal Care as super-
vised by the local Animal Care Committee of the
University of Guelph. Xenografts were established in
male and female RAG1
-/- mice by injecting 2 × 10
6
WM239 or SW480 cells in 100 μLo f0 . 5 %B S A / P B S
subcutaneously into the right flank. Tumor size was
monitored through caliper measurements taken every
third day, and volume calculated using the formula
(length × width
2)/2. Tumors were allowed to grow to
approximately 200 mm
3, and then mice were rando-
mized into treatment and control groups. Treatment
consisted of 20 mg/kg/day of cyclophosphamide mono-
hydrate (Sigma-Aldrich) in their drinking water[16].
Water for all mice was changed twice weekly for a per-
i o do fu pt o1 8d a y s ,m i c ew e r ee u t h a n i z e db yC O 2
asphyxiation and cervical dislocation, and tissue samples
were collected for analysis.
Blood Vessel Assessment
Formalin-fixed paraffin embedded sections of treated
and control SW480 and WM239 xenografts, and tissue
microarrays of human colorectal carcinoma (Tissue
Array Research Program, Centre for Cancer Research,
NCI, Frederick, MD, USA), and melanoma (Imgenex,
San Diego, CA, USA) were de-paraffinized and subjected
to a 10 mM sodium citrate buffer, pH 6.0 for antigen
retrieval. Sections were then incubated in DAKO Pro-
tein Block (DAKO, Mississauga, ON, Canada) for 1
hour. Antigen detection was performed sequentially by
first using goat polyclonal anti-CD31 primary antibody
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
then donkey anti-goat FITC-conjugated secondary anti-
body (1:200; Santa Cruz Biotechnology) for 30 minutes.
Sections were washed and then incubated with rabbit
anti-VEGFR2 (1:100; Cell Signaling, Boston, MA, USA)
o v e r n i g h ta t4 ° C ,f o l l o w e db yg o a ta n t i - r a b b i tC y 3
(1:200; Jackson ImmunoResearch, West Grove, PA,
USA) for 30 minutes. Antigen detection was performed
sequentially (as described above). For mural cell quanti-
fication, antigen retrieval was in Tris-EDTA buffer solu-
tion (pH 9.0), followed by DAKO Protein Block and 5%
donkey serum each for 30 minutes. Sections were incu-
bated with goat polyclonal anti-CD31 (1:100; Santa Cruz
Biotechnology) for 1 hour then donkey anti-goat FITC-
conjugated (1:200; Santa Cruz Biotechnology) for 30
minutes, followed by anti-smooth muscle actin, directly
conjugated to Cy3 (1:400; Sigma-Aldrich) for 30
minutes.
Five random fields of view at 200X magnification for
each xenograft specimen were captured in a blinded
fashion using QCapture software calibrated to a Leica
DMLB microscope with an attached Q imaging QICAM
fast1394 digital camera. One image/spot at 200X magni-
fication was captured from each specimen in human tis-
sue microarrays. Images were overlaid using Adobe
Photoshop 7.0 (Adobe, Toronto, ON, Canada). VEGFR2
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and negative, and total blood vessels per field were
quantified from overlaid images as previously reported
[15]. Briefly, positive blood vessels were characterized by
staining for both VEGFR2 or anti-smooth muscle actin
antibodies, and the pan-endothelial cell marker, CD31.
Vessel profiles with discontinuous CD31 staining were
counted as separate vessels. Branched vessels were
counted as a single vessel as long as staining for CD31
and/or VEGFR2 was continuous for the extent of the
visible blood vessel profile. Microvessel density was cal-
culated by dividing the total number of blood vessels
per field area to determine the number of blood vessels
per mm
2.
Immunohistochemistry for Hypoxia
Formalin-fixed paraffin embedded sections were de-par-
affinized, rehydrated and incubated in 3% H2O2 (Fisher,
Ottawa, ON, Canada) for 15 minutes, followed by anti-
gen retrieval with acidic citrate buffer as described
above. Sections were incubated in DAKO Protein Block
for 20 minutes followed by 5% normal goat serum (Vec-
tor, Burlington, ON, Canada) for 45 minutes and rabbit
anti-carbonic anhydrase-IX (1:500; Abcam, Cambridge,
MA, USA) overnight at 4°C. Slides were washed, incu-
bated in biotinylated goat anti-rabbit (1:500; Vector) for
30 minutes then treated with RTU Vectastain Elite,
ABC reagent (Vector) for 30 minutes followed by AEC
chromogen (Vector) for 5 minutes. Sections were coun-
terstained with Mayer’s hematoxylin (Sigma-Aldrich).
Relative hypoxic tissue (as CA-IX positive regions) to
total section surface area was calculated using the soft-
ware ImageScope (Aperio, Vista, CA, USA). Sections
were evaluated in a blinded fashion.
Western Blotting
Tissues were lysed with Cell Lysis Buffer (Cell Signaling
Technology) with added aprotinin, PMSF and Phospha-
tase Inhibitor Cocktail II (all from Sigma-Aldrich).
SDS-PAGE was performed with 90 micrograms of total
protein loaded into 7.5% polyacrylamide gels and pro-
teins were transferred to PVDF membranes (Roche) and
blocked in 5% milk/TBST. Membranes were probed
with the following primary antibodies overnight at
4ºC: rabbit anti-VEGFR2 (1:1000; Cell Signaling Tech-
nology), mouse anti-TSP-1 (1:500; Lab Vision), mouse
anti-tubulin (1:200,000; Sigma-Aldrich), mouse anti-
HIF1a (1:400, R&D Systems, Minneapolis, MN), rabbit
anti-desmin (1:1500; Abcam), goat anti-CD31 (1:800;
Santa Cruz Biotechnology), followed by secondary anti-
bodies goat anti-rabbit POD (1:5000 - 1:20,000), goat
anti-mouse POD (1:20,000) or rabbit anti-goat (1:20,000,
a l lf r o mS i g m a - A l d r i c h )f o r3 0m i n u t e sa tr o o mt e m -
perature. Protein bands of interest were detected with
Chemiluminescence Blotting Substrate (Roche), and
densitometry performed by normalization to tubulin
signal. For desmin blots, signal was normalized to CD31
for each sample.
In Vitro Cyclophosphamide Toxicity
Briefly, 1 × 10
4 cells were plated into each well in a 96
well plate in complete medium for 48 hrs then serum
starved for 24 hrs. Plates were then exposed to 0-
100,000 ng/ml 4-HC (4-hydroperoxycyclophosphamide;
HCNiomech/IIT GmbH, Bielefeld, DE; the precursor of
4-hydroxycyclophosphamide, the metabolically active
metabolite of cyclophosphamide) and incubated for 72
hours. MTT cytotoxicity assay was performed with a
Cell Growth Determination Kit using the manufacturer’s
protocol (Sigma-Aldrich, Oakville, ON) and absorbance
was read at 570 nm with an ELX800 Universal Micro-
plate Reader (BIO-TEK Instruments Inc, Winooski, VT).
Three independent replicates were preformed with each
dose done in triplicate.
VEGF-A ELISA
WM239 and SW480 cells were seeded into 6-well plates
at a density of 5.0 × 10
5 cells. The following day, media
was changed to DMEM and 2% FBS. 24 hours later,
media was replaced to DMEM and 2% FBS ± CoCl2
(100 μM), ± 4-HC (100 nM) or a combination of both.
24 hours after treatment, condition media was collected
and cell free supernatant was used to measure VEGF-A
levels with ELISA using a commercially available ELISA
kit (R & D Systems). Cells were counted to standardize
VEGF levels. Two independent experiments were per-
formed, and each sample analyzed as duplicates. Results
were presented as pg VEGF per 10,000 cells.
Quantification of TUNEL Reaction
Apoptosis was detected in paraffin embedded tissues
with the In Situ Cell Death Detection Kit, POD
(Roche), according to manufacturer’s instructions.
TUNEL-positive nuclei were identified with DAB sub-
strate chromogen system (DAKO) and counterstained
with Mayer’s hematoxylin (Sigma-Aldrich). Quantifica-
tion was performed in a blinded fashion by scoring the
number of positive nuclei/10 high power fields of non-
necrotic tissue. Five sections per group were analyzed
and averaged.
Statistical analysis
Comparison of means was performed using either the
Student’s t-test, or ANOVA followed by post-hoc analy-
sis using the Bonferroni and Tukey’s LSD methods. Dif-
ferences were considered significant when p ≤ 0.05.
Data are expressed as the mean and standard error of
the mean (SEM).
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VEGFR2 Status of Blood Vessels in Human Tumors
Dual immunofluorescence staining for VEGFR2 and
CD31 was performed on formalin-fixed paraffin
embedded tissue microarrays to determine the heteroge-
neous nature of VEGFR2 expression within the vascula-
ture of clinically relevant tumors. Colorectal carcinoma
(n = 36; on average approximately 20 blood vessels/tis-
sue core), and metastatic malignant melanoma (n = 14;
approximately 15 blood vessels/tissue core) were evalu-
ated. Heterogeneous expression of VEGFR2 was
observed in both tumor types (Figure 1; Table 1). Color-
ectal carcinoma had a significantly lower average per-
cent VEGFR2 positive blood vessels (60% VEGFR2
positive blood vessels) than malignant melanoma (93%
VEGFR2 positive blood vessels) (p < 0.05).
Conserved VEGFR2 Expression Patterns between
Xenograft and Human Clinical Tumors
The VEGFR2 status of vessels in colorectal carcinoma
and melanoma was compared between human clinical
samples and mice xenografted with human cancer cells
of the same type, and there were no significant differ-
ences in vascular phenotype between xenografts and
clinical cases within a cancer type (Table 1) (p < 0.05).
We consistently found that colorectal carcinoma xeno-
graft tumors had significantly fewer VEGFR2 positive
blood vessels than malignant melanoma xenografts.
Figure 1 Heterogeneous expression of VEGFR2 in melanoma and colorectal cancer. Dual immunofluorescent staining for VEGFR2 (red) and
CD31 (green) in human cancer specimens shows VEGFR2 negative blood vessels (arrows) and VEGFR2 positive blood vessels (asterisks). (A-C)
Metastatic malignant melanoma and (D-F) colorectal carcinoma have been divided into their respective channels (overlaid; green; red images).
Scale bar = 50 μm.
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Cyclophosphamide
To study the influence of this VEGFR2 heterogeneity on
response to low dose metronomic cyclophosphamide
therapy (CTX), we evaluated xenografts from treated
mice. No significant differences in tumor volume
between treated and control groups were observed for
either SW480 or WM239 xenografts (Figure 2A). Can-
cer cell toxicity to CTX was evaluated in vitro (Figure
2C), and the approximate LC50 of 3000 ng/ml is well
above the expected tissue levels of CTX under this
metronomic schedule[16]. Consistent with this we found
no significant difference in the incidence of cancer cell
apoptosis as detected by TUNEL positive nuclei (Figure
2D). Sections of tumors immunostained for CD31 were
then scored for microvessel density (MVD). CTX ther-
apy induced a significant reduction in MVD in both
SW480 and WM239 xenografts (p < 0.05; Figure 3A).
CTX treatment also induced a significant increase in the
levels of endogenous anti-angiogenic protein thrombos-
pondin 1 (TSP-1) in SW480 xenografts, but a significant
decrease in TSP-1 levels was seen in WM239 tumors
treated with CTX compared to control (p < 0.05; Figure
3C).
Influence of CTX on VEGFR2 Vascular Status
The effect of low dose metronomic cyclophosphamide
therapy on VEGFR2 expression was also characterized
(Figure 4A-D). There was a significant decrease in mean
density of VEGFR2 positive blood vessels between con-
trol and treated tumors for both SW480 and WM239
xenografts (p < 0.05; Figure 4E). Western blotting of
tumor proteins demonstrated a significant reduction in
total VEGFR2 between SW480 control and CTX tumors
(p < 0.05), but no significant changes in total VEGFR2
in WM239 (p < 0.05; Figure 4G).
Hypoxia in CTX and Control Tumors
We expected to see that successful angiogenic blockade
o fS W 4 8 0a n dW M 2 3 9x e n o g r a f t sw o u l dr e s u l ti n
increased tumor hypoxia. However, we found no signifi-
cant differences in HIF1-a levels between control and
CTX for either tumor type (Figure 5A), although the
average hypoxic area as demonstrated by CA-IX immu-
nostaining was significantly reduced in WM239 CTX
compared to control (p < 0.05; Figure 5C-G). While in
vitro induction of HIF1a in WM239 and SW480 cells
Table 1 Patterns of endothelial VEGFR2 expression in tumor blood vessels in xenografted tumors and clinical cancer
Tumor Type # of Tumors % VEGFR2 Positive % VEGFR2 Negative
SW480 xenograft 4 60 ± 10.57
a 40 ± 12.61
c
Clinical colorectal carcinoma 36 60 ± 3.06
a 40 ± 2.54
c
WM239 xenograft 10 91.96 ± 3.01
b 8.04 ± 0.41
d
Clinical metastatic melanoma 14 93 ± 3.29
b 7 ± 0.33
d
Table I - VEGFR2 heterogeneity was assessed in human clinical specimens and xenografts of both colorectal carcinoma and metastatic malignant melanoma
using dual immunofluorescence staining for VEGFR2 and CD31. The mean values for average percentage of VEGFR2 positive and VEGFR2 negative vessels were
calculated along with SEM. Values with the same superscript (a-m) are significantly different from the same vessel class in different cancer types, but not from
each other (p < 0.05).
Figure 2 Mice were treated orally with 20 mg/kg/day of
cyclophosphamide in their drinking water. Tumor growth curves
of low dose metronomic cyclophosphamide (CTX) treated and
control xenografts of (A) SW480, and (B) WM239 cells; Mean (SEM) is
plotted. No significant differences in growth rates were observed
between control and treated mice for either SW480 or WM239
xenografts. Cancer cell toxicity to CTX was evaluated in vitro using
the MTT assay (C). Apoptosis was quantified in tumor sections by
TUNEL reaction, and while rare TUNEL positive nuclei were seen in
cancer cells (white arrow in D), we did not find any TUNEL positive
endothelial cells (black arrows), nor any significant differences in
apoptotic cells between control and CTX tumors (E). Scale bar = 25
μm.
Patten et al. BMC Cancer 2010, 10:683
http://www.biomedcentral.com/1471-2407/10/683
Page 5 of 11(by CoCl2 exposure) lead to expected increases in
VEGF-A production, no significant difference were
observed between cells co-incubated with or without
CTX (Figure 5H) hence difference in response to CTX
between cell lines is not due to differential regulation of
VEGF-A expression.
Blood Vessel Alterations in Response to CTX
Our finding of reduced MVD but no increase in tumor
hypoxia suggests that tumor vessel functionality (i.e. per-
fusion) may have been improved in CTX treated tumors.
We found significant increases in the proportion of
a-SMA positive (i.e. “mature”) vessels in SW480 tumors
(p < 0.05; Figure 6A). There was also evidence that the
relative expression of the mural cell protein desmin was
increased in SW480 tumors treated with CTX compared
to control but not in WM239 xenografts (Figure 6).
Discussion
Targeting tumor vasculature as a cancer therapy is now
an established concept with the potential to benefit
patients with a wide variety of tumor types. However,
despite success in preclinical rodent studies this
approach had variable results in patients [17-23]. It is
now apparent that there are degrees of complexity in
the anti-angiogenic process, that the response to
its blockade is still not well understood and that cancer
cell specific factors influence tumor angiogenesis in
unexpected ways [24,25]. For instance, ‘resistance’ to
anti-angiogenic therapy could arise due to redundancy
of angiogenic factors, intrinsic or induced co-option of
surrounding vasculature, preferential recruitment of
bone marrow derived cells that facilitate vascular survi-
val, etc.[26,27]. We have previously demonstrated that
heterogeneity of endothelial cell Tie2 expression influ-
ences anti-angiogenic responses [15]. Here, we explore
the impact of VEGFR2 expression patterns in vascula-
ture of colorectal carcinoma (CRC) and malignant mela-
noma on responses to angiogenic blockade induced by
low dose metronomic (LDM) cyclophosphamide.
LDM scheduling of standard cytotoxic agents exerts
its therapeutic effect by targeting the endothelial cells of
the tumor vasculature, rather than the rapidly dividing
cancer cells [4,28-30]. LDM cyclophosphamide (CTX)
may exert its anti-angiogenic effect through the up-reg-
ulation of TSP-1, shown to target the VEGF/VEGFR2
signaling axis by binding and displacing VEGF
[4,6,31-33]. Since SW480 CRC xenografts contained sig-
nificantly lower proportions of VEGFR2 positive vessels
(compared to malignant melanoma), we predicted that
superior anti-tumor responses to LMD CTX would
occur in WM239 malignant melanoma xenografts. How-
ever, despite effective angiogenic blockade in both
tumor types, no decreases in tumor volume were seen.
Increased progression of experimental tumors during
LDM chemotherapy has previously been reported
[29,30,34,35], and recent studies indicate that VEGF sig-
naling blockade can also increase cancer cell invasive-
ness and metastasis [24,25]. Interestingly, although
melanoma and CRC xenografts showed significant
decreases in MVD in our study, only CRC demonstrated
concomitant increases in TSP-1 expression. This sug-
gests that response to LDM CTX is cancer cell specific.
The higher percentage of VEGFR2 positive blood ves-
sels observed here in malignant melanoma may be indi-
cative of greater reliance on VEGF signaling for tumor
angiogenesis in this cancer type. Circulating serum
levels of VEGF are significantly higher in melanoma
patients compared to controls [36], and VEGF-TRAP
induced robust anti-vascular and anti-tumor effects in
xenografted human melanoma [37]. In fact, WM239
cells themselves express VEGFR2 [Additional file 1: Sup-
plemental Figure S1], thus VEGFR2 detected in tumor
l y s a t e si so fd u a lc e l lo r i g i n ,w h i c hp r o b a b l ya c c o u n t s
for the lack of significant change in VEGFR2 levels over-
all, despite significant alterations in the proportion of
VEGFR2 positive vessels. Tip cells at the leading edge of
vascular sprouts express low levels of the Notch-1 and
-4 receptors, high levels of their ligand Delta like 4
(Dll4), and low levels of their ligand Jagged, while stalk
cells, which form the bulk of the growing sprout are low
in Dll4, low in Notch, and high in Jagged[38-40]. This
Figure 3 Microvessel density (MVD) as CD31 positive profiles
in SW480 and WM239 subcutaneous xenografts; Mean (SEM)
are plotted. There were significant reductions in MVD in both
SW480 (A) and WM239 (B) xenografts between CTX and control
groups (*p < 0.05). Western blotting of tumor lysates for TSP-1
revealed significant increases in TSP-1 levels in CTX treated SW480
tumors compared to control (C; *p < 0.05), but significant decreases
in CTX treated WM239 tumors compared to control (D; *p < 0.05).
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Page 6 of 11Figure 4 Effect of low dose metronomic cyclophosphamide therapy on vascular VEGFR2 status. Examples of VEGFR2 positive blood
vessels (chevrons) and VEGFR2 negative blood vessels (arrows) are shown in WM239 (A) treated and (B) control and SW480 (C) treated and (D)
control subcutaneous xenografts. Scale bar = 50 μm. Quantification of immunofluorescence showed significant decreases in the density of
VEGFR2 positive vessels in CTX treated SW480 (E) and WM239 (F) tumors (*p < 0.05). Total VEGFR2 protein levels in tissue lysates were
significantly reduced in SW480 tumors treated with CTX (*p < 0.05), but not in treated WM239 tumors (G, H).
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(via Notch/Dll4) or stimulation (via Notch/Jagged) of
development of tip cell phenotype and hence formation
of sprouts[40]. Interestingly, Dll4 signaling through
Notch-1 or -4 leads to reduced expression of VEGFR2
in stalk cells[38,41], thus the VEGFR2 free vascular pro-
f i l e sw er e p o r th e r ei nC R Cm a yr e p r e s e n tt h es t a l k so f
sprouting microcirculation.
Indirectly targeting VEGF in murine xenografts may
lead to blood vessel normalization [6,42]. When tumor
Figure 5 Effect of low dose metronomic cyclophosphamide therapy on tumor hypoxia.H I F 1 - a levels in tumor lysates were not
significantly different between CTX and control tumors for either SW480 (A) or WM239 (B). Representative images of tumor cross sections
immunostained for CA-IX (dark reaction product) and counterstained with hematoxylin: WM239 CTX (C) and control (D); SW480 CTX (E) and
control (F). Insert of panel (C) is negative control without primary antibody. Scale bars = 300 μm. G) Quantification of hypoxic regions (Mean;
SEM) in SW480 and WM239 xenografts from CTX and control mice. Treated WM239 xenograft tumors had significantly lower average percent
hypoxic regions than control (*p < 0.05). No significant difference was observed between CA-IX staining in SW480 CTX and control tumors. H, I)
Measurement of conditioned medium by ELISA demonstrates that 24 hour treatment in vitro with CoCl2 induced up-regulation in VEGF
expression in both cell lines (H; SW480; I, WM239), while treatment with low dose 4-HC does not. Combining these treatments had no additive
effect over the induction produced by CoCl2 alone.
Patten et al. BMC Cancer 2010, 10:683
http://www.biomedcentral.com/1471-2407/10/683
Page 8 of 11vasculature is normalized, there is pruning of superfluous
‘immature’ vessel sprouts, modulation of the pathologi-
cally thick basement membrane via activation of matrix
metalloproteinases, and increased pericyte coverage
mediated by the upregulation of angiopoietin-1[42].
These morphological changes are accompanied by func-
tional alterations such as decreased interstitial fluid pres-
sure, increased tumor oxygenation and improved drug
penetration into tumors[11,13,43-46]. In our study, we
did not see clear-cut evidence for vascular normalization.
While LDM CTX induced several morphological features
consistent with enhanced vessel stabilization (increased
desmin expression and a-SMA positive mural cell
recruitment) in CRC, this did not occur in malignant
melanoma tumors despite significant angiogenic blockade
in both systems. The lack of increase in TSP-1 produc-
tion by WM239 cells in response to LDM CTX may
have led to altered VEGF signaling in tumor endothelial
cells, and hence no changes in mural cell recruitment or
vessel stability in these xenografts.
Tumor blood vessels are abnormal in function and
structure [10,47,48], leading to regions of transient and
chronic ischemia within solid tumors including our
CRC and melanoma xenografts. Since microvessel den-
sity was significantly decreased in treated WM239
tumors, we expected to see concomitant increased
tumor hypoxia [49]. Instead, hypoxic regions decreased,
but in the absence of detectable vessel “normalization”,
suggesting that vessel responses to LDM CTX in mela-
noma may differ from that of carcinomas. Vessel nor-
malization is transient[42] and the time frame and
kinetics of vessel normalization in malignant melanoma
has yet to be determined. Further studies are required
to determine whether blood flow is increased in the
remaining melanoma vasculature after LDM CTX
induced angiogenic blockade, which would account for
reduced regions of tumor hypoxia.
Most studies of experimental anti-angiogenic treat-
ment report reduced vessel density with parallel reduc-
tions in tumor volume, which was not seen here for
either cell line. Our previous work demonstrated that
WM239 cells can develop a reduced requirement for
vascular dependence and hence enhanced survival
despite reduced vessel density[50], which may account
for the lack of tumor shrinkage seen here. It has also
been well documented that ischemic conditions within
solid tumors can lead to genetic instability and subse-
quently tumor progression[51,52]. We have previously
shown that 48 hrs exposure to ischemia in vitro could
induce de novo KRAS mutations in human CRC cells
[53]. Accelerated CRC tumor progression due to KRAS
mutation was also induced in LDM CTX treated xeno-
grafts despite a significant anti-angiogenic effect[35]. A
similar event whereby increased ischemia leads to
Figure 6 Effect of low dose metronomic cyclophosphamide
therapy on vascular mural cell recruitment. A) Dual
immunofluorescent staining for vascular alpha smooth muscle actin
(a-SMA; red) and CD31 (green) showing blood vessels positive
(chevrons) and negative (arrows) for this mural cell marker. Scale bar
=5 0μm. B) CTX treated SW480 xenograft tumors had significantly
increased proportion of a-SMA positive blood vessels compared to
control (*p < 0.05). No significant difference was observed between
CTX and control WM239 tumors. The ratio between the mural cell
marker protein desmin and pan endothelial marker CD31 was
assessed by western blotting of whole tumor lysates (C) LDM CTX
treatment resulted in increased desmin content realtive to CD31 for
SW480 but not WM239 xenografts.
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gression may be occurring in SW480 tumors here.
Conclusions
Based on the variable results observed clinically when
targeting angiogenesis to treat cancer, we hypothesized
that heterogeneous VEGFR2 expression could be
responsible for some of the therapeutic outcomes
reported to date[54]. Here we demonstrate significant
heterogeneity in endothelial VEGFR2 expression in
human colorectal carcinoma and CRC xenografts.
Despite this, there was robust anti-angiogenic response
to metronomic cyclophosphamide chemotherapy,
thought to indirectly target the VEGF/VEGFR2 pathway
via TSP-1 upregulation. WM239 malignant melanoma
xenografts, which display more consistent VEGFR2 vas-
cular expression, also underwent significant reductions
in vascular density despite no appreciable change in
TSP-1 production. Our findings thus indicate that
responses to LDM anti-angiogenic therapy may be
highly cancer cell dependent. Further studies are
required to determine whether endothelial VEGFR2 het-
erogeneity, rather than the cancer cell response per se,i s
mediating anti-angiogenic effects in LDM therapy. The
mechanisms controlling heterogeneous VEGFR2 expres-
sion patterns in different types of cancer also call for
investigation, as these potentially could impact
responses to targeted anti-angiogenic approaches in a
cancer specific fashion.
Additional material
Additional file 1: Supplemental Figure S1. Analysis of VEGFR2
expression by WM239 malignant melanoma cells
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